Abstracts tagged "Abatacept"

Abstract Number: 1840 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes Following Exposure to Abatacept during Pregnancy
M Kumar¹, L Ray¹, S Vemuri² and T Simon¹, ¹Bristol-Myers Squibb, Hopewell, NJ, ²Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Limited data are currently available in the medical literature to guide counseling of patients regarding pregnancy outcomes when treated with abatacept, a selective T-cell…
Abstract Number: 132 • 2014 ACR/ARHP Annual Meeting
Do Ultrasound (PDUS) and DAS28 Measure Different Aspects of Disease Activity? Analyses from the First Prospective International Phase IIIb Study of PDUS Response in Abatacept-Treated Patients with Rheumatoid Arthritis (RA)
Maria-Antonietta d'Agostino¹, M Boers², R Wakefield³, H Berner Hammer⁴, O Vittecoq⁵, M Galeazzi⁶, P Balint⁷, I Möller⁸, A Iagnocco⁹, E Naredo^10,11, M Ostergaard¹², C Gaillez¹³, E Barre¹⁴, M Le Bars¹⁵ and On behalf of the OMERACT-EULAR-Ultrasound Task Force, ¹AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ²VU University Medical Center, Amsterdam, Netherlands, ³University of Leeds, Leeds, United Kingdom, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵University Hospital, Rouen, France, ⁶University of Siena, Siena, Italy, ⁷Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁸Instituto Poal, Barcelona, Spain, ⁹Sapienza Università di Roma, Roma, Italy, ¹⁰Hospital Universitario Severo Ochoa, Madrid, Spain, ¹¹Hospital GU Gregorio Marañón, Madrid, Spain, ¹²Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ¹³Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ¹⁴Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ¹⁵Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: A composite (power Doppler/grayscale ultrasound [PDUS]) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, was shown to be responsive in RA patients with inadequate…
Abstract Number: 1578 • 2014 ACR/ARHP Annual Meeting
Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis – Preliminary Analysis from a Single Centre, Placebo-Controlled, Crossover Study
Agnes Szentpetery¹, Eric J. Heffernan², Muhammad Haroon³, Phil Gallagher¹, Anne-Marie Baker¹, Martina Cooney¹ and Oliver FitzGerald¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Radiology, St. Vincent's University Hospital, Dublin, Ireland, ³Newmarket On Fergus, Cork University Hospital, Cork, Ireland
Background/Purpose Abatacept is a soluble, fully human fusion protein which selectively inhibits T-cell activation via the CD80/CD86:CD28 co-stimulation pathway and decreases serum levels of inflammatory…
Abstract Number: 1532 • 2014 ACR/ARHP Annual Meeting
Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
Rossella Reggia¹, Franco Franceschini¹, Angela Tincani² and Ilaria Cavazzana¹, ¹AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy…
Abstract Number: 1536 • 2014 ACR/ARHP Annual Meeting
Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 1515 • 2014 ACR/ARHP Annual Meeting
The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate
T W J Huizinga¹, S E Connolly², Daniel E. Furst³, Vivian P. Bykerk⁴, Gerd Burmester⁵, B G Combe⁶, C S Karyekar², D Wong², L Trouw¹, R E M Toes⁷ and P Emery⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³University of California at Los Angeles, Los Angeles, CA, ⁴Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁵Charité – University Medicine Berlin, Berlin, Germany, ⁶Montpellier University Hospital, Montpellier, France, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a marker of RA and may contribute to disease progression.1,2 ACPA analysis in patients offers the opportunity to estimate…
Abstract Number: 1520 • 2014 ACR/ARHP Annual Meeting
Gene Expression Analyses of Abatacept- and Adalimumab-Treated Patients from the Ample Trial
S Bandyopadhyay¹, M Maldonado¹, M Schiff², ME Weinblatt³, Roy Fleischmann⁴ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The distinct mechanisms of action (MoA) of abatacept (ABA) and adalimumab (ADA) are expected to manifest in different transcriptional profiles in RA patients (pts).…
Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Anders Gülfe¹, Johan A. Karlsson² and Lars-Erik Kristensen³, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ³Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…
Abstract Number: 504 • 2014 ACR/ARHP Annual Meeting
Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries
Axel Finckh¹, David Neto², M. Victoria Hernández³, Florenzo Iannone⁴, Elisabeth Lie⁵, Helena Canhao⁶, K Pavelka⁷, Carl Turesson⁸, Xavier Mariette⁹, Merete Lund Hetland¹⁰ and Jacques Gottenberg¹¹, ¹Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²University of Geneva, Geneva, Switzerland, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ⁷Institute of Rheumatology, Prague, Czech Republic, ⁸Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ¹⁰DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose Some observations have suggested that the effectiveness of abatacept (ABA) may be decreased in rheumatoid arthritis (RA) patients (pts) who previously failed rituximab (RTX).(1)…
Abstract Number: 501 • 2014 ACR/ARHP Annual Meeting
Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics – Results from the National Swedish Rheumatology Quality Register
Carl Turesson¹, Leszek Stawiarz², Staffan Lindblad³ and Saedis Saevarsdottir⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…
Abstract Number: 2923 • 2014 ACR/ARHP Annual Meeting
Protein Quantification Using Mass Spectrometry Methods to Predict Response to Abatacept and Methotrexate Combination Therapy in Rheumatoid Arthritis
A Obry^1,2, P Cosette², T Lequerré^1,3, Maria-Antonietta d'Agostino⁴, C Gaillez⁵, M Le Bars⁶ and O Vittecoq^1,3, ¹Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²UMR 6270 CNRS, PISSARO Proteomic Facility, IRIB, Normandy University, University of Rouen, Rouen, France, ³Department of Rheumatology, Rouen University Hospital, Rouen, France, ⁴AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁵Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Targeted biologic therapies with different mechanisms of action are commonly used in RA. Abatacept is a recombinant fusion protein that inhibits T-cell co-stimulatory molecules…
Abstract Number: 516 • 2014 ACR/ARHP Annual Meeting
The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study
Shinya Hirabara¹, Toshihisa Kojima², Nobunori Takahashi², Yuji Hirano¹, Atsushi Kaneko³, Daihei Kida⁴, Yasuhide Kanayama⁵ and Naoki Ishiguro², ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan, ⁵Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan
Background/Purpose: Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often…
Abstract Number: 2504 • 2014 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT), a selective co-stimulation modulator, is the first in a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that…
Abstract Number: 510 • 2014 ACR/ARHP Annual Meeting
Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept – Results from the National Swedish Rheumatology Quality Register
Carl Turesson¹, Leszek Stawiarz², Staffan Lindblad³ and Saedis Saevarsdottir⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…
Abstract Number: 2492 • 2014 ACR/ARHP Annual Meeting
Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study
H Nüßlein¹, R Alten², M Galeazzi³, HM Lorenz⁴, MT Nurmohamed⁵, WG Bensen⁶, Gerd Burmester⁷, H-H Peter⁸, P Peichl⁹, K Pavelka¹⁰, M Chartier¹¹, C Poncet¹², C Rauch¹³ and M Le Bars¹⁴, ¹Internistische Schwerpunktpraxis, Nürnberg, Germany, ²Schlosspark-Klinik University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵VU Univ Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Charité-Universitätsmedizin, Berlin, Germany, ⁸University of Freiburg, Freiburg, Germany, ⁹Evangelisches Krankenhaus, Vienna, Austria, ¹⁰Institute of Rheumatology, Charles University, Prague, Czech Republic, ¹¹Chiltern International, Neuilly, France, ¹²Docs International, Nanterre, France, ¹³Bristol-Myers Squibb, Munich, Germany, ¹⁴Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In RA, reduced efficacy with anti-TNF therapy1 and dose escalation2 have been reported for obese patients (pts) compared with non-obese pts. Clinical trials have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].